Programmed cell death factor 4 (PDCD4), a novel therapy target for metabolic diseases besides cancer

Free Radic Biol Med. 2020 Nov 1:159:150-163. doi: 10.1016/j.freeradbiomed.2020.06.016. Epub 2020 Jul 31.

Abstract

Programmed cell death factor 4 (PDCD4) is originally described as a tumor suppressor gene that exerts antineoplastic effects by promoting apoptosis and inhibiting tumor cell proliferation, invasion, and metastasis. Several investigations have probed the aberrant expression of PDCD4 with the progression of metabolic diseases, such as polycystic ovary syndrome (PCOS), obesity, diabetes, and atherosclerosis. It has been ascertained that PDCD4 causes glucose and lipid metabolism disorders, insulin resistance, oxidative stress, chronic inflammatory response, and gut flora disorders to regulate the progression of metabolic diseases. This review aims to summarize the latest researches to uncover the structure, expression regulation, and biological functions of PDCD4 and to elucidate the regulatory mechanism of the development of tumors and metabolic diseases. This review has emphasized the understanding of the PDCD4 role and to provide new ideas for the research, diagnosis, and treatment of tumors and metabolic diseases.

Keywords: Glucose metabolism; Inflammation; Intestinal flora; Lipid metabolism; Oxidative stress; PDCD4.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Apoptosis
  • Apoptosis Regulatory Proteins / genetics
  • Apoptosis Regulatory Proteins / metabolism
  • Cell Line, Tumor
  • Female
  • Humans
  • Insulin Resistance*
  • Polycystic Ovary Syndrome*
  • RNA-Binding Proteins

Substances

  • Apoptosis Regulatory Proteins
  • PDCD4 protein, human
  • RNA-Binding Proteins